

Source details

Annals of Medicine and Surgery


Scopus coverage years: from 2012 to Present
(coverage discontinued in Scopus)

Publisher: Elsevier

E-ISSN: 2049-0801

Subject area: Medicine: Surgery

Source type: Journal

CiteScore 2022 
1.7

SJR 2022 
0.387



SNIP 2022 
0.765

[View all documents >](#)


[Set document alert](#)

 [Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)


 Improved CiteScore methodology 

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

CiteScore 2022 

$$1.7 = \frac{5,570 \text{ Citations 2019 - 2022}}{3,335 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023 

$$2.4 = \frac{7,967 \text{ Citations to date}}{3,380 \text{ Documents to date}}$$

Last updated on 05 September, 2023 • Updated monthly

CiteScore rank 2022

Category	Rank	Percentile
Medicine Surgery	#269/495	45th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site !\[\]\(23a2e9ddc7bb0ef55393d38b772a848d_img.jpg\)](#)

Works Where You Write

Grammarly
Ins:

Annals of Medicine and Surgery

COUNTRY

Netherlands

Universities and research institutions in Netherlands

Media Ranking in Netherlands

SUBJECT AREA AND CATEGORY

Medicine
Medicine (miscellaneous)
Surgery

PUBLISHER

Elsevier BV

H-INDEX

36

PUBLICATION TYPE

Journals

ISSN

20490801

COVERAGE

2012-2022

INFORMATION

[Homepage](#)
[How to publish in this journal](#)
annalsjournal@elsevier.com

Submit Paper for Publication

IJFMR - Academic Journal
01

SCOPE

Annals of Medicine and Surgery is an online-only, peer-reviewed open access journal with a global outlook and focus on those training in medicine and surgery (postgraduate and undergraduate). AMS contains a mix of original clinical and basic science research, reviews, editorials, commentary, perspectives, debate, opinion, case reports and journal club reports. The journal crosses the whole disease spectrum of medicine and surgery but does also have a special focus on

the following areas: -Patient safety- Human factors, teamwork, communication and professionalism- Quality improvement science and practice- Evidence based medicine- Implementation science – clinical evidence into practice- Leadership and management- Medical education, teaching, and training- Public and global health- Healthcare policy, delivery, commissioning, and resource management- Use of technology and health informatics- Clinical ethics and medical law- Research and innovation – bedside to bench and back again – including applications like personalised medicine.

Join the conversation about this journal

[x](#)


Submit Paper for Publication




IJFMR - Academic Journal
Op

Quartiles

FIND SIMILAR JOURNALS ?

<p>1</p> <p>International Journal of Surgery</p> <p>NLD</p>	<p>2</p> <p>International Journal of Surgery Open</p> <p>GBR</p>	<p>3</p> <p>International Journal of Surgery Case Reports</p> <p>NLD</p>	<p>4</p> <p>BMC Surgery</p> <p>GBR</p>	<p>5</p> <p>Acta C</p> <p>GBR</p>
<p>80%</p> <p>similarity</p>	<p>73%</p> <p>similarity</p>	<p>67%</p> <p>similarity</p>	<p>61%</p> <p>similarity</p>	








% International Collaboration

Citable documents

Non-citable documents

Cited documents

Uncited documents



Annals of Medicine and Surgery

Q3 Medicine (miscellaneous) best quartile

SJR 2022 0.39

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç
```

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool.**

Metrics based on Scopus® data as of April 2023



Loading comments...

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®





ISSN 2090-0695

ANNALS OF MEDICINE & SURGERY



www.annalsjournal.com

ScienceDirect



Annals of Medicine and Surgery

Editorial Board

Editor-in-Chief

Riaz Agha, London, England, UK

Assistant Managing and Executive Editor

Maliha Agha, London, England, UK

Assistant Editors

Adam Frampton, London, England, UK
Jorg Kleef, Munich, Germany
Deepthi Mani, Washington, USA
David Rosin, Bridgetown, Barbados
Peter Schemmer, Heidelberg, Germany

Social Media Editor

Riaz Agha, London, UK

Managing Editor

Alexander James Fowler, London, England, UK

Statistical Editor

Lai-Chu See, Taoyuan, Taiwan

Associate Staff Editors

Sergio Acuna, Toronto, Canada
Guido Alsfasser, Rostock, Germany
Fernando Angarita, Toronto, Canada
James Clark, Plymouth, England, UK
Terry Evans, London, England, UK
Shivani Garg, Wisconsin, USA
Todd Golden, Arizona, USA
Fermin Guerrero Del Angel, Madero, Mexico
Eleni Ntouvali, Athens, Greece

Assistant Commissioning Editors

Ahmed Al-Jabir, London, UK
Zaid Alsafi, London, UK
Thomas Franchi, Sheffield, UK
Christos Iosifides, London, UK
Ahmed Kerwan, London, UK

Mehdi Khan, London, UK
Ginimol Mathew, London, UK
Maria Nicola, London, UK
Niamh O'Neill, London, UK
Catrin Sohrabi, London, UK

Junior Staff Editors

Sumita Agrawal, Jodhpur, India
Bakir Al-Dulaimy, London, UK
Mohammed Anwar, London, UK
Martinique Vella Baldacchino, Glasgow, UK
Maria Borrelli, London, UK
Kerry Anne Burke, Manchester, England, UK
Adam Cristaudo, Cairns, Australia
Buket Gundogan, London, UK
Adam Gwozdz, London, England, UK

Mike Hu, California, USA
Tobin Joseph, London, UK
Kiron Koshy, London, UK
Seon-Young Lee, Southampton, England, UK
Chris Limb, London, England, UK
Yasser Al Omran, London, England, UK
Karishma Shah, Oxford, UK
Rachel Thavayogan, London, UK

Executive Committee

Sir Graeme Catto, Aberdeen, Scotland, UK
Sir Barry Jackson, London, England, UK

David Rosin, Bridgetown, Barbados

Editorial Board

Xiao-Ping Chen, Wuhan, China
Marc Cohen, Victoria, Australia
David Green, London, England, UK
Saeed Sadiq Hamid, Karachi, Pakistan
Peter Hutchinson, Cambridge, England, UK
Peter Littlejohns, London, England, UK
Ashok Mahapatra, New Delhi, India
Judy McKimm, Swansea, Wales, UK
Dattatraya Muzumdar, Mumbai, India

Ashish Nabar, Mumbai, India
Fabio Nicoli, London, UK
John Norcini, Philadelphia, PA, USA
Christoph Paasch, Berlin, Germany
Daniel Sokol, London, England, UK
Jamsheer Talati, Karachi, Pakistan
John V. Thomas, Birmingham, AL, USA
Tim Gabe Williams, Kent, England, UK
Zhao-Fan Xia, Shanghai, China

Elsevier

Executive Publisher

Allan Ross, New York, USA

Administrative Editor

Joanne Frankland, Oxford, UK

Marketing Manager

Wendy Montalvo, New York, USA

Journal Manager

Tamsyn Hopkins, Exeter, UK

Senior Business Development

Executive (Reprints)

Emma Steel, London, UK

Advertising Sales Manager

Robert Bayliss, London, UK

Account Manager (Supplements)

Evelina Euren, The Netherlands



Annals of Medicine and Surgery

Open access

Menu



Search in this journal

Volume 74

February 2022

[< Previous vol/issue](#)

[Next vol/issue >](#)

Open access

Editorial Board

Article 103357



[View PDF](#)

Original Research

Research article [Open access](#)

Surgical patient satisfaction with a virtual hybrid care hotel model: A retrospective cohort study

Ryan M. Chadha, Margaret R. Paulson, Francisco R. Avila, Ricardo A. Torres-Guzman, ... Michael J. Maniaci

Article 103251



[View PDF](#)

[Article preview](#)

Research article [Open access](#)

Colorectal cancer survival rates in Makassar, Eastern Indonesia: A retrospective Cohort Study

Ibrahim Labeda, Ronald Erasio Lusikooy, Mappincara, Muhammad Iwan Dani, ... Muhammad Faruk

Article 103211



[View PDF](#)

[Article preview](#)

Research article [Open access](#)

Comparison of Doppler Ultrasound and Digital Subtraction Angiography in extracranial stenosis

Seyed Farzad Maroufi, Seyedeh Niloufar Rafiee Alavi, Mohammad Hossein Abbasi, Ali Famouri, ... Mohammad Taghi Joghataei

Article 103202



[View PDF](#)

[Article preview](#)

[FEEDBACK](#)

Research article [Open access](#)

The effect of protein supplements on weight loss, body composition, protein status, and micronutrients post laparoscopic sleeve gastrectomy (LSG): A Randomised Controlled Trial (RCT)

Sahar Alshamari, Mohamed Aly Elsherif, Fahad Hanna, Leyan El Akhal, ... Wahiba Elhag

Article 103220



[View PDF](#)

[Article preview](#)

Research article [Open access](#)

Synthesis and anti-*Toxoplasma* activity of indole-triazole compounds on tachyzoites of RH strain

Mohammad Saleh Bahreini, Aida Iraj, Najmeh Edraki, Ali Arab Monfared, Qasem Asgari

Article 103245



[View PDF](#)

[Article preview](#)

Case report [Open access](#)

Fracture of the humeral surgical neck and shoulder dislocation following an epileptic seizure: Case report


Hidar Alibrahim, Mohamed Wahedi, Mohammed Rajab Almohammed, Sarya Swed, Mohamad Morjan
Article 103323

 [View PDF](#) [Article preview](#) 

Case report [Open access](#)

Post COVID-19 hemorrhagic pericardial effusion; A case report with literature review

Bnar J. Hama Amin, Fahmi H. Kakamad, Ahmed Gh Hamasaeed, Abdulwahid M. Salih, ... Bestoon KH. Salih
Article 103300

 [View PDF](#) [Article preview](#) 

Case report [Open access](#)

A suspected surgical case of acute abdomen: A case report of scrub typhus


Sunil Basukala, Shriya Sharma, Ayush Tamang, Ujwal Bhusal
Article 103329

 [View PDF](#) [Article preview](#) 

Case report [Open access](#)

Sclerochoroidal calcification associated with chondrocalcinosis: A clinical case



O. Nabih, H. Hamdani, L. EL Maaloum, B. Allali, A. EL kettani
Article 103275

 [View PDF](#) [Article preview](#) 

Case report [Open access](#)

En-plaque sphenoid wing grade II meningioma: Case report and review of literature



Baha'eddin A. Muhsen, Abdelmajid I. Aljariri, Hasan Hashem, Qasem Alzoubi, ... Abdellatif Al Mousa
Article 103322

 [View PDF](#) [Article preview](#) 

Case report [Open access](#)

A female with isolated hypogonadotropic hypogonadism: A case report and review article

Ariella Maisie Sugiarto, Soebagijo Adi Soelistijo
Article 103289

 [View PDF](#) [Article preview](#) 

Case report [Open access](#)

Emphysematous pyelonephritis: A rare case report from Syria



Maher Al-Hajjaj, Mohamed Tallaa
Article 103281

 [View PDF](#) [Article preview](#) 

Case report [Open access](#)

Contralateral epidural hematoma after decompressive surgery: Case report and systematic literature review

Abdelkoudous Laaidi, Abderrahmane Rafiq, Yassine Tahrir, Said Hilmani, Abdelhakim Lakhdar
Article 103233


 [View PDF](#) [Article preview](#) 

Case report [Open access](#)

A case of limbic encephalitis associated with severely COVID-19 infection

Amine Elmouhib, Hicham Benramdane, Fatima zohra Ahsayen, Inass Arhoun El Haddad, ... Brahim Housni
Article 103274

 [View PDF](#) [Article preview](#) 



Case Report

A female with isolated hypogonadotropic hypogonadism: A case report and review article



Ariella Maisie Sugiarto, Soebagijo Adi Soelistijo *

Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

ARTICLE INFO

Keywords:

Hypogonadotropic hypogonadism
Estradiol
Gonadotropins
Fertility

ABSTRACT

Background: Isolated Hypogonadotropic Hypogonadism (IHH) is a clinical syndrome that results from gonadal failure due to abnormal pituitary gonadotropin levels, in the presence of normal baseline and reserve testing of the remaining pituitary hormones.

Case presentation: An 18 years old female came with primary amenorrhea, accompanied by poor breast and pubic development, with low levels of estradiol and gonadotropins but normal levels of other anterior pituitary hormones. Imaging of the hypothalamic-pituitary region revealed hypophyseal hypoplasia due to ischemia. Sex steroids therapy was given to induce pubertal development. IHH represents a rare condition but with a good prognosis.

Discussion: Early diagnosis and treatment can prevent negative physical and psychological sequelae, and restore fertility in affected patients. Constant surveillance is required due to the possibility of gonadal axis reversal and/or relapse of gonadal axis failure and to identify any adverse effects related to therapy.

Conclusion: Early identification of IHH can help in treatment efficiency.

1. Introduction

Hypogonadotropic hypogonadism (HH) or secondary hypogonadism is defined as a clinical syndrome that results from gonadal failure due to abnormal pituitary gonadotropin levels. HH may result from either absent or inadequate hypothalamic Gonadotropin-Releasing Hormone (GnRH) secretion or failure of pituitary gonadotropin secretion. It is typically characterized by a lack or delay of pubertal sexual maturation and inappropriately low circulating sexual steroids associated with low serum concentrations of Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH), which is an effect of GnRH deficiency. HH is most frequently acquired and caused by several pathological processes, but it can also occur as part of various congenital syndromes with genetic causes of central hypogonadism have been identified. Idiopathic or isolated HH (IHH) was then used to indicate cases in which secondary causes of HH had been excluded [1–3].

Congenital HH is divided into anosmic HH (Kallmann syndrome) and congenital normosmic IHH. The incidence of congenital hypogonadotropic hypogonadism is approximately 1–10:100,000 live births, and approximately 2/3 and 1/3 of cases are caused by Kallmann syndrome

(KS) and idiopathic HH, respectively [2,4]. HH is one of the rare conditions in which specific medical treatment can reverse infertility. The precise and early diagnosis of HH can prevent negative physical and psychological sequelae, preserve normal peak bone mass, and restore fertility in affected patients. Thus, clinicians should understand the characteristics of the condition and be able to recognize and treat the condition to guarantee patients' quality of life [3,5]. Based on the description above, we are interested in reporting an 18-year-old female patient with IHH. We report based on surgical case report (SCARE) 2020 guideline [6].

2. Case presentation

An 18-year-old female came with primary amenorrhea, accompanied with poor breast and pubic hair development. The patient did not report eating disorders, vigorous physical activity, or psychological stress. She had no olfactory complaints. She had 1 older brother with a history of normal pubertal development. There was no history of opiates, glucocorticoid, or psychotropic drugs administration. On a physical examination, she had no apparent congenital anatomical defects with normal

* Corresponding author. Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Jl. Mayjend Prof. Dr. Moestopo No. 6-8, Airlangga, Gubeng, Surabaya, East Java, 60286, Indonesia.

E-mail address: soebagijo1121@gmail.com (S.A. Soelistijo).

<https://doi.org/10.1016/j.amsu.2022.103289>

Received 22 December 2021; Received in revised form 13 January 2022; Accepted 23 January 2022

Available online 26 January 2022

2049-0801/© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

habitus, height: 157 cm, arm span: 156 cm, weight: 61 kg, and normal body mass index (24.7 kg/m²). Pubic hair and breast development were tanner stage II-III. Her bone age was 13 years old. At the time, the patient had already received hormonal therapy from the gynecology department for 2 months (Primolut 1 × 5mg and Esthero 1 × 0.625mg), with cyclical bleeding occurring regularly following therapy. Before therapy, there was poor development of breasts and pubic hair until the age of 18, so the possibility of Constitutional Delay of Puberty can be ruled out. Both anamnesis and physical examination showed clinical characteristics suggestive of HH, with functional (drugs, eating disorder, physical activity, stress) and autoimmune causes being ruled out. Serum karyotype examination such as 46, XX (N), ruling out gonadal dysgenesis. Basal hormonal evaluation revealed low serum estradiol 7.245 pg/mL (N 11–133 pg/mL) and serum progesterone 0.08 pg/mL (N 0.21–60 pg/mL). Laboratory result on June 2019 showed suppressed LH 0.03 mIU/mL (N 0.7–5.6 mIU/mL) and FSH 0.23 mIU/mL (N 1.5–10.2 mIU/mL). Anterior pituitary function were otherwise normal, prolactin 3.52 ng/mL (N 2.8–29.2 ng/mL), insulin 8.80 mU/L (N 0.5–300 mU/L), Growth Hormone 1.96 ng/mL (N 0.05–40.0), TSH 3.586 uIU/mL (N 0.55–4.78 uIU/mL), FT4 1.15 ng/dL (N 0.89–1.76 ng/dL), cortisol 10.55 µg/dL (N 4.3–22.4 µg/dL), ACTH 12.0 pg/mL (N <46 pg/mL), FBG 86 mg/dL, 2 hour post prandial BG 89 mg/dL. Ferritin test 112 ng/mL (N 20–278 ng/mL). All laboratory studies are suggestive of IHH with serum ferritin and other antepituitary hormones concentrations within normal limit, ruling out the possibility of hemochromatosis and other pituitary cause.

Abdominal ultrasound examination revealed uterus hypoplasia (1.4 × 2.4 × 3.4 cm). Pelvic MRI confirmed uterus hypoplasia and revealed no apparent normal ovaries (Fig. 1). MRI of the hypothalamic-pituitary region revealed hypophyseal hypoplasia (Fig. 2) with small vessel ischemic in right and left corona radiata and right temporal subcortical with MR Angiography showed right segment A1, ACA hypoplasia (embryonal variant). There were no radiological signs suggestive of Kallman syndrome.

The patient was assessed with isolated HH with no additional therapy from the endocrinology polyclinic and was recommended to continue her outpatient care in both endocrinology and gynaecology polyclinic regularly.

3. Discussion

In both males and females, secretion of LH and FSH is episodic, with secretory bursts that occur each hour and are mediated by a concordant episodic release of GnRH. Pulsatile secretion of GnRH by hypothalamic neurons is a crucial element of the reproductive cascade, initiating the release of pituitary gonadotropins, gonadal secretion of sex steroids, pubertal development, and gametogenesis. LH and FSH bind to receptors in the ovary and testis and regulate gonadal function by promoting sex steroid production and gametogenesis. In women, LH stimulates estrogen and progesterone production from the ovary. A surge of LH in the mid-menstrual cycle is responsible for ovulation, and continued LH secretion subsequently stimulates the corpus luteum to produce progesterone by enhancing the conversion of cholesterol to pregnenolone. Development of the ovarian follicle is largely under FSH control, and the secretion of estrogen from this follicle is dependent on both FSH and LH [3,7].

The diagnosis of IHH is confirmed by the findings of low levels of sex steroids (total testosterone (T) <100 ng/dL in males and estradiol (E2) <50 pg/mL in females) in the presence of low or inappropriately normal LH and FSH serum levels with typically normal levels of other anterior pituitary hormones. Acute stimulation with GnRH (GnRH test) is of little value in differentiating between a hypothalamic and pituitary defect. Most patients with GnRH deficiency show little or no response to an initial dose of GnRH, but normal responses may be elicited after repeated injections, in the presence of a hypothalamic defect. This initial slow response is attributed to the down-regulation of GnRH receptors after prolonged GnRH deficiency. Although widely used, the practical



Fig. 1. MRI of hypoplasia uterus 1.

value of the GnRH test has been questioned because of its low cost-effectiveness. Indeed, the GnRH test provides no extra diagnostic information relative to baseline gonadotropin levels. The anterior pituitary function must be investigated by basal hormonal levels to rule out a more complex endocrine disorder with multiple hormone deficiencies. Thyroid function should be assessed by TSH combined with free T4. Secondary adrenal deficiency can be assessed by measuring morning cortisol and ACTH. Because sex steroids are necessary for growth, performing a bone age measurement should be considered in all hypogonadal patients, who may have delayed bone age compared with chronologic age [3,8,9].

Hormonal replacement therapy is required to induce pubertal development, to maintain normal sexual function and avoid osteoporosis. In women, replacement therapy can be started initially with low-dose estrogen (ethinyl estradiol 5 µg or conjugated estrogen 0.3 mg daily). After 6 months or sooner, if breakthrough bleeding occurs, cyclical therapy is initiated by adding a progestin for endometrial




Fig. 2. Hypophyseal hypoplasia with small vessel ischemic.

protection, and the dose of estrogen is gradually increased to 20–30 μg over a 2- to 3-year period so as to respect the normal cadence of puberty. Full replacement dose of estrogen and progesterone is attained with 0.625–1.25 mg conjugated equine estrogen daily combined with cyclic 5–10 mg medroxyprogesterone acetate or 200 mg oral micronized progesterone [10,11].

If fertility is desired, treatment with gonadotropins or GnRH is needed to induce ovulation. In women, the gonadotropin regimen is initiated with purified human Menopausal Gonadotropin (hMG) at a starting dose of 37.5 IU/d IM, the dose being carefully titrated upward to 75–150 IU/d using cycle tracking by ultrasonography. Ideally, monofollicular growth is induced, and if the leading follicle is bigger than 18 mm, human Chorionic Gonadotropin (hCG) is administered at a dose of 5,000 to 10,000 IU IM to induce ovulation. Luteal support with one to two IM injections of hCG (2000–5000 IU) is subsequently required. Pulsatile GnRH therapy can be used as an alternative to gonadotropins, being equally or more effective. GnRH pulses (75–250 ng/kg for women) are administered, SC or intravenously, by a portable infusion pump with an interpulse frequency of 120 minutes [12,13].

Reversal of HH, defined as restoration of normal serum gonad concentrations after cessation of even brief treatment with sex steroids, gonadotropin, or GnRH, occurs in about 10% of all HH cases, including those with Kallman Syndrome. This post-treatment awakening of the hypothalamo-pituitary-gonadal (HPG) axis suggests the presence of hypothalamic GnRH neurons that do not function during adolescence and possibly require undefined stimuli (potentially environmental/sex steroid exposure) to initiate normal activity. The precise physiologic basis of the reversal phenomenon is yet to be fully understood but previous studies have shown a role of androgen exposure as a common factor for reversal. The androgen exposure can either be due to exogenous testosterone or via endogenous testosterone production stimulated by HCG/GnRH. It has been known that sex steroids can influence a neuronal generation. The increased androgen levels have been proposed to stimulate GnRH cells and regeneration of GnRH neurons by taking advantage of the plasticity of GnRH neurons. Another feature seen in previous studies is a relapse of hypogonadism in those who have achieved reversal due to the susceptibility of the gonadotropic axis to insult. Thus constant surveillance of patients with HH on therapy is important

to look for adverse effects, or even the possibility of reversal of axis and/or further relapse [14–17].

4. Conclusion

An 18 years old female patient with IHH has been reported. IHH is defined as a clinical syndrome that results from gonadal failure due to abnormal pituitary gonadotropin levels, in the presence of normal baseline and reserve testing of the remaining pituitary hormones. Clinical presentations may vary according to age, however, the patient came with complaints of primary amenorrhea and poor breasts, and pubic hair development. The diagnosis of IHH is confirmed by the findings of low levels of estradiol in the presence of low or inappropriately normal LH and FSH serum levels with typically normal levels of other anterior pituitary hormones. MRI of the hypothalamic-pituitary region revealed hypophyseal hypoplasia due to ischemia. The patient received sex steroids therapy from the gynaecology department to induce pubertal development. IHH represents a rare condition with a good prognosis in which specific medical treatments can reverse infertility. Due to the possibility of gonadal axis reversal and/or relapse of gonadal axis failure and to identify any adverse effects related to long term hormonal therapy, the patient should be closely monitored during therapy and constant surveillance is required.

Ethical approval

Not applicable.

Sources of funding

None.

Author contribution

All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Registration of research studies

Not applicable.

Guarantor

Soebagijo Adi Soelistijo.

Provenance and peer review

Not commissioned, externally peer reviewed.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgment

We thank our editor “Fis Citra Ariyanto”.

References

- [1] P. Skałba, M. Guz, Hypogonadotropic hypogonadism in women, *Endokrynol. Pol.* 62 (6) (2011) 560–567.
- [2] R. Fraietta, D.S. Zylberstejn, S.C. Esteves, Hypogonadotropic hypogonadism revisited, *Clinics* 68 (Suppl 1) (2013) 81–88, [https://doi.org/10.6061/clinics/2013\(sup01\)09](https://doi.org/10.6061/clinics/2013(sup01)09), Suppl 1.
- [3] L.F. Silveira, A.C. Latronico, Approach to the patient with hypogonadotropic hypogonadism, *J Clin Endocrinol Metab* 98 (5) (2013) 1781–1788, <https://doi.org/10.1210/jc.2012-3550>.
- [4] S.D. Bianco, U.B. Kaiser, The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism, *Nat. Rev. Endocrinol.* 5 (10) (2009) 569–576, <https://doi.org/10.1038/nrendo.2009.177>.
- [5] S. Yilmaz, A.S. Ozgu-Erdinc, O. Yumusak, S. Kahyaoglu, B. Seckin, N. Yilmaz, The reproductive outcome of women with hypogonadotropic hypogonadism undergoing in vitro fertilization, *Syst. Biol. Reprod. Med.* 61 (4) (2015) 228–232, <https://doi.org/10.3109/19396368.2015.1037936>.
- [6] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, A. Kerwan, The SCARE 2020 guideline: updating consensus surgical Case Report (SCARE) guidelines, *Int. J. Surg.* 84 (2020) 226–230, <https://doi.org/10.1016/j.ijsu.2020.10.034>.
- [7] A.M. Blanco, Hypothalamic- and pituitary-derived growth and reproductive hormones and the control of energy balance in fish, *Gen. Comp. Endocrinol.* 287 (2020) 113322, <https://doi.org/10.1016/j.ygcen.2019.113322>.
- [8] R. Balasubramanian, W.F. Crowley Jr., Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network, *Mol. Cell. Endocrinol.* 346 (1–2) (2011) 4–12, <https://doi.org/10.1016/j.mce.2011.07.012>.
- [9] F.K. Yilmazel, İ. Karabulut, A.H. Yılmaz, E. Keskin, F. Bedir, İ. Özbey, A review of hypogonadotropic hypogonadism cases followed up in our clinic in the last decade, *Urologia* 88 (1) (2021) 50–55, <https://doi.org/10.1177/0391560319882231>.
- [10] C. Ankarberg-Lindgren, B. Kriström, E. Norjavaara, Physiological estrogen replacement therapy for puberty induction in girls: a clinical observational study, *Hormone Res Paediatr* 81 (4) (2014) 239–244, <https://doi.org/10.1159/000356922>.
- [11] K.O. Klein, S.A. Phillips, Review of hormone replacement therapy in girls and adolescents with hypogonadism, *J. Pediatr. Adolesc. Gynecol.* 32 (5) (2019) 460–468, <https://doi.org/10.1016/j.jpag.2019.04.010>.
- [12] R. Maggi, A.M. Cariboni, M.M. Marelli, R.M. Moretti, V. André, M. Marzagalli, et al., GnRH and GnRH receptors in the pathophysiology of the human female reproductive system, *Hum. Reprod. Update* 22 (3) (2016) 358–381, <https://doi.org/10.1093/humupd/dmv059>.
- [13] G.A. Stamatiades, U.B. Kaiser, Gonadotropin regulation by pulsatile GnRH: signaling and gene expression, *Mol. Cell. Endocrinol.* 463 (2018) 131–141, <https://doi.org/10.1016/j.mce.2017.10.015>.
- [14] T. Raivio, J. Falardeau, A. Dwyer, R. Quinton, F.J. Hayes, V.A. Hughes, et al., Reversal of idiopathic hypogonadotropic hypogonadism, *N. Engl. J. Med.* 357 (9) (2007) 863–873, <https://doi.org/10.1056/NEJMoa066494>.
- [15] V.F. Sidhoum, Y.M. Chan, M.F. Lippincott, R. Balasubramanian, R. Quinton, L. Plummer, et al., Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system, *J Clin Endocrinol Metab* 99 (3) (2014) 861–870, <https://doi.org/10.1210/jc.2013-2809>.
- [16] J.F. Mao, H.L. Xu, J. Duan, R.R. Chen, L. Li, B. Li, et al., Reversal of idiopathic hypogonadotropic hypogonadism: a cohort study in Chinese patients, *Asian J. Androl.* 17 (3) (2015) 497–502, <https://doi.org/10.4103/1008-682x.145072>.
- [17] O. Rashid, N. Ram, S. Farooq, Z. Kiran, Idiopathic hypogonadotropic hypogonadism reversal after testosterone replacement in a 34-year-old male, *BMJ Case Rep.* 2017 (2017), <https://doi.org/10.1136/bcr-2016-218729>.